Member Info for HedgeHogarth

Just goes to show, no smoke without fire.

Good news on debt facility - guarantees them another 6-7 weeks to get their hands on the diamonds

Must be close - can't imagine the banks would have extended again without confidence in the diamond recovery

To be fair, the recent developments have all been positive and the company raised £1.7m at 0 35p.

So for me, those with deeper pockets that me and who will have done their due diligence were happy that 0.35p was a discounted opportunity to invest in Vast. The banks have also been supportive.

I expect the share price has only stayed at this level for a while to help fill some bigger orders.

I think this will move up very soon, maybe towards 0.5p

To be fair, the recent developments have all been positive and the company raised £1.7m at 0 35p.

So for me, those with deeper pockets that me and who will have done their due diligence were happy that 0.35p was a discounted opportunity to invest in Vast. The banks have also been supportive.

I expect the share price has only stayed at this level for a while to help fill some bigger orders.

I think this will move up very soon, maybe towards 0.5p

A lot didnt

Apologies - put a double negative in there! For avoidance of doubt, i don't think this is a heavily 'traded' share

Pleasantly surprised that I've been able to top-up in the 18s which is only about 10% higher than the 6mth low of 16.5 which has been tested twice.

This does not strike me as a share that is NOT heavily 'traded'. If my interpretation of the RNS is shared in the broader market (i.e. it's very good!) I would expect to see the growth in the share price to come over a period of weeks / months/

This does not seem to be related to Hemo at all - its sounds like a innovative opportunity to fight cancer - but cant see a link to Hemo

1. This drug is very early in the process (ph 1 trials)

2. In preclinical research, it was shown to be effective in treating cells derived from breast, prostate, brain, ovarian, cervical, skin and lung cancers. NOTE - nothing to suggest this is anything to do with Blood cancers which is the main objectve for Hemo

Oh no, a third!

India the Family

I do not believe they are invested in Hemo - But the comments in relation to Biotech, especially small ones, felt very relevant to the Hemo conversation.

In the meantime - not another Mr / Mrs India ;-(

£1 bet that Phoenix just sold a few shares to make this start Red

A great update from XP Factory

The company has grown significantly over the last 3-4 years and now seeing the benefits

Great to see the growth coming through in both Boom Bars and Escape Rooms - both are really innovative entertainment brands and still nowhere near their peak participation.

I expect Boom Bars in particular will have a huge Xmas this year - the Commercial team at my company have used them this year for a big event and the feedback was awesome.

For those that are new to the stock - worth checking out the history of this company under it's old name "Escape Hunt". The market cap was significantly higher even before the acquisition of the very exciting Boom Bars

https://disfold.com/company/escape-hunt-plc/marketcap/

This is a market leader in two innovative ventures - and could make it to mid cap status in the next few years if it continues to grow at current rate

GLA

Ironically - 3 more posts proving point.

I'm well aware of FFWD

Your points only strengthen my point here - yes the history is chequered, but the subsequent share price decline seems overdone and has left a very compelling investment opportunity.

Cash - Tick

Huge discount to NAV - Tick

Far, far too much effort from one or a few on here to downplay this investment

I smell a rat

RNS released today from the RTW Venture Fund

RTW Venture Fund (RTWVF) is focused on innovative biotech and medtech businesses that have clear pathways to delivering approved medicines and medical technologies to patients. It is managed by RTW Investments (RTW), a New York-headquartered, life sciences investment firm with offices in London and Shanghai. RTW takes a science-led, full-lifecycle approach to investing in both public and private opportunities, supporting companies at all stages of development via multiple capital solutions. Biotech stocks, in particular those of smaller-cap companies, fell out of favour in early 2021, but started to recover from mid-2022. RTW’s managers are hopeful that the sector’s positive fundamentals are starting to be appreciated again and that positive developments at portfolio companies will generate significant value for RTWVF’s shareholders. The fund’s largest holding recently received a takeover bid at a c 75% premium to its pre-bid share price.

https://www.edisongroup.com/research/finding-value-in-the-out-of-favour-biotech-sector/32268/

Phoenix - been here for years with an 4p average etc and just the 7 posts on LSE - says it all really

You are all probably right in your own ways. It sounds like the CEO has made errors of judgement in the past and for those who were impacted by this will feel aggrieved and not want to trust him.

However, as DJP says - it now looks a very compelling investment opportunity. Perhaps the drop was overdone: now sits at a huge discount to NAV, it has cash in the bank and is an opportunity for new and existing investors to benefit.

Almost 4pm, looks like day traders plotting final moves

If you look back at my history - I offered a very credible scenario that could see underpin a big increase in this SP - although clearly reliant on progress at Planet Hemo

Too late - I just did

Seems to be far too much interest trying to talk this share down; discussing the past and making bold accusations. You really know what Ed's friends are doing or not doing?...

I suggest people judge this investment on its current merits - not what happened in the past

Looks like MMs have done a great job here for their big clients

The Bid has dropped regularly - but the ask has bee more resilient - obviously a lot of demand for shares at these levels